Aspire Biopharma Holdings, Inc. (ASBP)

US — Healthcare Sector
Peers:

Automate Your Wheel Strategy on ASBP

With Tiblio's Option Bot, you can configure your own wheel strategy including ASBP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ASBP
  • Rev/Share 0.0
  • Book/Share -0.8954
  • PB -0.4076
  • Debt/Equity -0.9729
  • CurrentRatio 0.2216
  • ROIC 132.2327

 

  • MktCap 18076979.0
  • FreeCF/Share -0.2461
  • PFCF -9.4583
  • PE -0.1003
  • Debt/Assets 3.4414
  • DivYield 0
  • ROE 12.764

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
ASBP
Published: August 13, 2025 by: Accesswire
Sentiment: Neutral

BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize their performance potential 30,000 BUZZ BOMB™ sample packs of four 50mg stick packs in each flavor distributed to convention attendees Well-known fitness instructors, fitness celebrities, athletes, and influencers along with thousands of fitness enthusiasts and consumers sampled BUZZ BOMB™'s four bold flavors As part of its launch, Aspire plans on partnering with well-known athletes and influencers across fitness training and endurance sports to accelerate consumer awareness and uptake BUZZ BOMB™ is available for purchase at buzzbomb.buzz , the Company's new …

Read More
image for news Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
ASBP
Published: July 22, 2025 by: Accesswire
Sentiment: Neutral

Sublingual nano technology delivers 50mg of caffeine rapidly to the body, bringing its unique benefits to the pre-workout market ESTERO, FL / ACCESS Newswire / July 22, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending supplement delivery technology, today announced it plans to launch its newsublingual pre-workout supplement, BUZZ BOMB™, at FitCon and FitExpo, two of the largest fitness conventions held annually in Salt Lake City, Utah (August 1-2) and Anaheim, CA, (August 2-3), respectively. Featuring 50mg of caffeine and designed to support sustained energy and mental focus, BUZZ BOMB™ is bringing …

Read More
image for news Aspire Biopharma Holdings, Inc. to Launch its BUZZ BOMB Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World
Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation
ASBP
Published: April 29, 2025 by: Accesswire
Sentiment: Neutral

Company achieves another milestone relating to its clinical trial strategy HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that it has received Institutional Review Board (IRB) approval of the clinical trial protocol for its upcoming Phase I single-center clinical trial in the United States designed to evaluate safety, pharmacokinetics and pharmacodynamics, of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation. One clinical trial site has been activated with patient enrollment expected …

Read More
image for news Aspire Biopharma Holdings, Inc., Announces Institutional Review Board Approval for In-Human Clinical Trial of an Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation

About Aspire Biopharma Holdings, Inc. (ASBP)

  • IPO Date 2022-04-11
  • Website https://aspirebiolabs.com
  • Industry Biotechnology
  • CEO Kraig T. Higginson
  • Employees 2

Aspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.